Summit Therapeutics Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert W. Duggan
- Full Time Employees
- 265
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 601 Brickell Key Drive Miami FL United States of America 33131
- IPO Date
- Mar 5, 2015
- CIK
- 0001599298
- Website
- smmttx.com
- Similar Companies
- Business
- Summit Therapeutics Inc. (Nasdaq: SMMT) is a biopharmaceutical company focused on the discovery, development, and commercialization of oncology therapies. The company develops ivonescimab, a novel bispecific antibody combining PD-1 blockade for immunotherapy with anti-VEGF-mediated anti-angiogenesis effects; ivonescimab is in global Phase III clinical trials, including HARMONi and HARMONi-3 for EGFR-mutated non-small cell lung cancer (NSCLC), HARMONi-6 for squamous NSCLC, HARMONi-7, and the recently announced HARMONi-GI3 for first-line metastatic colorectal cancer, with over 2,800 patients treated to date across trials. Summit holds exclusive licenses for ivonescimab in the United States, Canada, Europe, Japan, Latin America, the Middle East, and Africa, while partner Akeso, Inc. retains rights in other regions and conducts trials in China and Australia. Founded in 2003 and headquartered in Miami, Florida, with additional offices in Menlo Park, California, and Oxford, UK, the company targets solid tumors such as NSCLC and colorectal cancer. Recent developments include a $500 million private placement in October 2025 to fund operations and U.S. trial site openings for HARMONi-GI3 by year-end; collaborations with Pfizer to combine ivonescimab with antibody-drug conjugates and with Revolution Medicines for RAS(ON) inhibitors in NSCLC, pancreatic ductal adenocarcinoma, and colorectal cancer; positive HARMONi-6 top-line results in 2025 showing a 40% reduction in progression or death risk in squamous NSCLC; and completion of HARMONi enrollment with favorable survival trends in Western patients.
Company News
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway
Daiichi Sankyo and AstraZeneca Enter into Clinical Trial Collaboration with Summit Therapeutics to Evaluate Datroway® in Combination with Ivonescimab Across Multiple Tumor Types
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up – What’s Next?
AstraZeneca's $2 Billion Vote of Confidence Leaves Summit Therapeutics Trading Well Below Street Targets
Summit Shares Jump on $2B Strategic Investment From AstraZeneca
Summit Stock Jumps 17% on $2 Billion AstraZeneca Investment
AstraZeneca Invests in Summit Therapeutics after Year of Speculation
Summit Therapeutics jumps 20% after AstraZeneca's $2 billion bet: what it signals
AstraZeneca invests $2 billion in Summit Therapeutics in cancer drug deal
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs
AstraZeneca to invest $2 billion in Summit Therapeutics for cancer drug tie-up
AstraZeneca Makes $2 Billion Strategic Equity Investment in Summit Therapeutics
HARMONi-GI1, a Phase III Trial Featuring Ivonescimab Plus Chemotherapy Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer from China, to Be Showcased in Presidential Symposium at ESMO 2026
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patients
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu